&nbsp;

Oct 2024

Drug

anastrozole

Other Name(s): Arimidex®

Quick Link(s):

Jun 2025

Regimen

AVD+BREN

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

New Drug Funding Program

Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2025

Document

[PDF]

ACCUBreastFactSheet-Inuit.pdf

New

Jun 2025

Drug

niraparib / abiraterone

Other Name(s): Akeega™

Quick Link(s):

Updated

Jul 2025

Drug

atezolizumab (subcut)

Other Name(s): Tecentriq® SC

Quick Link(s):

Updated

Jul 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Updated

Jul 2025

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Updated

Jul 2025

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Updated

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)